Drug-Induced Psychosis

  • Oliver Freudenreich
Part of the Current Clinical Psychiatry book series (CCPSY)


A wide variety of drugs can cause psychosis that is transient once the drug is removed. Some drugs cause such a transient, drug-induced psychosis in most people who take them (e.g., LSD and PCP), and other drugs cause psychosis only in a minority of susceptible patients (e.g., cannabis). This chapter reviews common drugs associated with psychosis: alcohol and sedative (during intoxication and withdrawal), cannabis, stimulants, LSD and hallucinogens, and PCP. The difficulties in making a diagnosis of drug-induced psychosis vis-à-vis a primary psychotic disorder are discussed, particularly as more potent designer drugs are easily available today, and psychosis can be prolonged. The public health ramifications of high-potency cannabis as a risk factor for schizophrenia are emphasized.


Drug-induced psychosis Diagnosis Treatment Urine drug testing Alcohol Sedative Cannabis Stimulants Methamphetamine LSD Hallucinogens PCP Ketamine Medication-induced psychosis Toxins 


  1. 1. Jim Morrison Available from: Accessed on 7/1/2019.
  2. 2.
    Feduccia AA, Holland J, Mithoefer MC. Progress and promise for the MDMA drug development program. Psychopharmacology. 2018;235:561–71.CrossRefGoogle Scholar
  3. 3.
    Grunebaum MF, Galfalvy HC, Choo TH, Keilp JG, Moitra VK, Parris MS, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175:327–35.CrossRefGoogle Scholar
  4. 4.
    Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev. 2004;23:45–9.CrossRefGoogle Scholar
  5. 5.
    Martinak B, Bolis RA, Black JR, Fargason RE, Birur B. Dextromethorphan in cough syrup: the poor man’s psychosis. Psychopharmacol Bull. 2017;47:59–63.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Mustonen A, Niemela S, McGrath JJ, Murray GK, Nordstrom T, Maki P, et al. Adolescent inhalant use and psychosis risk – a prospective longitudinal study. Schizophr Res. 2018;201:360–6.CrossRefGoogle Scholar
  7. 7.
    Adorjan K, Odenwald M, Widmann M, Tesfaye M, Tessema F, Toennes S, et al. Khat use and occurrence of psychotic symptoms in the general male population in Southwestern Ethiopia: evidence for sensitization by traumatic experiences. World Psychiatry. 2017;16:323.CrossRefGoogle Scholar
  8. 8.
    Huestis MA, Tyndale RF. Designer drugs 2.0. Clin Pharmacol Ther. 2017;101:152–7.CrossRefGoogle Scholar
  9. 9.
    Starzer MSK, Nordentoft M, Hjorthoj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175:343–50.CrossRefGoogle Scholar
  10. 10.
    Caton CL, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry. 2005;62:137–45.CrossRefGoogle Scholar
  11. 11.
    Caton CL, Hasin DS, Shrout PE, Drake RE, Dominguez B, Samet S, et al. Predictors of psychosis remission in psychotic disorders that co-occur with substance use. Schizophr Bull. 2006;32:618–25.CrossRefGoogle Scholar
  12. 12.
    Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000;9:28–37.CrossRefGoogle Scholar
  13. 13.
    McCain CF, Namey LB, Freudenreich O. Lamotrigine cross-reactivity with phencyclidine in rapid urine toxicology in a research study. Prim Care Companion CNS Disord. 2018;20(4) pii. 17l02192.Google Scholar
  14. 14.
    van Harten PN, van Trier JC, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry. 1998;59:128–30.CrossRefGoogle Scholar
  15. 15.
    Tsuang JW, Irwin MR, Smith TL, Schuckit MA. Characteristics of men with alcoholic hallucinosis. Addiction. 1994;89:73–8.CrossRefGoogle Scholar
  16. 16.
    Soyka M, Naber G, Volcker A. Prevalence of delusional jealousy in different psychiatric disorders. An analysis of 93 cases. Br J Psychiatry. 1991;158:549–53.CrossRefGoogle Scholar
  17. 17.
    Isenberg-Grzeda E, Kutner HE, Nicolson SE. Wernicke-Korsakoff-syndrome: under-recognized and under-treated. Psychosomatics. 2012;53:507–16.CrossRefGoogle Scholar
  18. 18.
    Freund SA, Banning AS. Synthetic cannabinoids: a review of the clinical implications of a new drug of choice. JAAPA. 2017;30:1–4.CrossRefGoogle Scholar
  19. 19.
    Drummer OH, Gerostamoulos D, Woodford NW. Cannabis as a cause of death: a review. Forensic Sci Int. 2019;298:298–306.CrossRefGoogle Scholar
  20. 20.
    Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42:1262–9.CrossRefGoogle Scholar
  21. 21.
    Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2:1483–6.CrossRefGoogle Scholar
  22. 22.
    Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.CrossRefGoogle Scholar
  23. 23.
    D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57:594–608.CrossRefGoogle Scholar
  24. 24.
    Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15:195–204.CrossRefGoogle Scholar
  25. 25.
    Arunogiri S, Foulds JA, McKetin R, Lubman DI. A systematic review of risk factors for methamphetamine-associated psychosis. Aust N Z J Psychiatry. 2018;52:514–29.CrossRefGoogle Scholar
  26. 26.
    Tang Y, Martin NL, Cotes RO. Cocaine-induced: psychotic disorders presentation, mechanism, and management. J Dual Diagn. 2014;10:98–105.CrossRefGoogle Scholar
  27. 27.
    Freudenreich O, Cather C, Holt D. Stimulant misuse in college for “pseudo-attention deficit disorder” during schizophrenia prodrome. Am J Psychiatry. 2006;163:2019.CrossRefGoogle Scholar
  28. 28.
    Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380:1128–38.CrossRefGoogle Scholar
  29. 29.
    Brewer JD, Meves A, Bostwick JM, Hamacher KL, Pittelkow MR. Cocaine abuse: dermatologic manifestations and therapeutic approaches. J Am Acad Dermatol. 2008;59:483–7.CrossRefGoogle Scholar
  30. 30.
    The Guardian. Basel in the spotlight: the city that learned to love LSD. 2018 Available from: Accessed on 7/1/2019.
  31. 31.
    Barrett FS, Griffiths RR. Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci. 2018;36:393–430.CrossRefGoogle Scholar
  32. 32.
    Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8Google Scholar
  33. 33.
    Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74:399–405.CrossRefGoogle Scholar
  34. 34.
    Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620–30.CrossRefGoogle Scholar
  35. 35.
    Baldridge EB, Bessen HA. Phencyclidine. Emerg Med Clin North Am. 1990;8:541–50.PubMedGoogle Scholar
  36. 36.
    Freudenreich O, Brown HE, Holt DJ. Psychosis and schizophrenia. In: Stern TA, Fava M, Wilens TE, Rosenbaum JF, editors. Massachusetts General Hospital comprehensive clinical psychiatry. 2nd ed. Philadelphia: Elsevier; 2016. p. 307–23.Google Scholar
  37. 37.
    Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics. 2012;53:103–15.CrossRefGoogle Scholar

Additional Resources

    Web Sites

    1. – The National Institute on Drug Abuse (NIDA) website. NIDA is the branch of the NIH that studies addictions.
    2. – NIDA’s section on club drugs.


    1. Huxley A. The doors of perception. New York: Harper & Brothers; 1954. – The English writer Huxley describes his psychedelic experiences under mescaline. His philosophical insights make this book worth reading today, particularly as psychiatry rediscovers the therapeutic values of mind-altering drugs. While you may never use psychedelic substances yourself, the book may open your mind (sorry about this pun which is intended) to the limits of day-to-day experiences.Google Scholar


    1. Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15:195–204. – A good overview over the changes in potency of cannabis products and the unresolved public health questions.CrossRefGoogle Scholar
    2. Nour MM, Carhart-Harris RL. Psychedelics and the science of self-experience. Br J Psychiatry. 2017;210:177–9. – A topic that I did not cover in detail: the therapeutic use of currently mostly illicit psychedelic substances. Psilocybin for example is being tested for use in cancer patients with depression and existential concerns.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Oliver Freudenreich
    • 1
  1. 1.Department of PsychiatryMassachusetts General HospitalBostonUSA

Personalised recommendations